These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29204893)

  • 21. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
    Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
    J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of itch symptoms in psoriasis: results from physician interviews and patient focus groups.
    Globe D; Bayliss MS; Harrison DJ
    Health Qual Life Outcomes; 2009 Jul; 7():62. PubMed ID: 19580674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
    Kimball AB; Luger T; Gottlieb A; Puig L; Kaufmann R; Nikaï E; Zhu B; Edson-Heredia E; Carlier H; Lin CY; Goldblum O; Yosipovitch G
    J Am Acad Dermatol; 2016 Dec; 75(6):1156-1161. PubMed ID: 27692498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.
    McCollister D; Shaffer S; Badesch DB; Filusch A; Hunsche E; Schüler R; Wiklund I; Peacock A;
    Respir Res; 2016 Jun; 17(1):72. PubMed ID: 27301413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The experience of pain and redness in patients with moderate to severe plaque psoriasis.
    Martin ML; Gordon K; Pinto L; Bushnell DM; Chau D; Viswanathan HN
    J Dermatolog Treat; 2015 Oct; 26(5):401-5. PubMed ID: 25822169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.
    Shikiar R; Bresnahan BW; Stone SP; Thompson C; Koo J; Revicki DA
    Health Qual Life Outcomes; 2003 Oct; 1():53. PubMed ID: 14613569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
    Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
    Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Vulvodynia Experience Questionnaire: Qualitative Development of a New Patient-Reported Outcome Measure for Vulvodynia.
    Goldstein AT; Diez PMQ; Kapanadze S; Cala ML; Evans CJ; Whyte JL; Christoph A
    J Sex Med; 2020 Oct; 17(10):2055-2066. PubMed ID: 32900670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.
    Strober B; Greenberg JD; Karki C; Mason M; Guo N; Hur P; Zhao Y; Herrera V; Lin F; Lebwohl M
    BMJ Open; 2019 Apr; 9(4):e027535. PubMed ID: 31005939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and Content Validity Testing of Patient-Reported Outcome Items for Children to Self-Assess Symptoms of the Common Cold.
    Halstead P; Arbuckle R; Marshall C; Zimmerman B; Bolton K; Gelotte C
    Patient; 2020 Apr; 13(2):235-250. PubMed ID: 31858430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS).
    Alexis A; Daniels SR; Johnson N; Pompilus F; Burgess SM; Harper JC
    J Drugs Dermatol; 2014 Mar; 13(3):333-40. PubMed ID: 24595580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies.
    Yosipovitch G; Reich A; Steinhoff M; Beselin A; Kent T; Dossenbach M; Berggren L; Henneges C; Luger T
    Dermatol Ther (Heidelb); 2018 Dec; 8(4):621-637. PubMed ID: 30465321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.
    McCarrier KP; Atkinson TM; DeBusk KP; Liepa AM; Scanlon M; Coons SJ;
    Clin Ther; 2016 Apr; 38(4):794-810. PubMed ID: 27041408
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.
    Gelhorn HL; Tong S; McQuarrie K; Vernon C; Hanlon J; Maclaine G; Lenderking W; Ye X; Speck RM; Lackman RD; Bukata SV; Healey JH; Keedy VL; Anthony SP; Wagner AJ; Von Hoff DD; Singh AS; Becerra CR; Hsu HH; Lin PS; Tap WD
    Clin Ther; 2016 Apr; 38(4):778-93. PubMed ID: 27041409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ramaekers BLT; Wolff RF; Pouwels X; Oosterhoff M; Van Giessen A; Worthy G; Noake C; Armstrong N; Kleijnen J; Joore MA
    Pharmacoeconomics; 2018 Aug; 36(8):917-927. PubMed ID: 29480455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
    Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
    J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of a novel patient-reported outcome measure to assess signs and symptoms of COVID-19.
    Romano C; Fehnel S; Stoddard J; Sadoff J; Lewis S; McNulty P; Chan EKH; Evans E; Jamieson C; Slagle AF; Mangel A; McQuarrie K
    J Patient Rep Outcomes; 2022 Jul; 6(1):85. PubMed ID: 35904710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The patient-reported impact of scars measure: development and validation.
    Brown BC; McKenna SP; Solomon M; Wilburn J; McGrouther DA; Bayat A
    Plast Reconstr Surg; 2010 May; 125(5):1439-1449. PubMed ID: 20440163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument.
    Johnson CD; Arbuckle R; Bonner N; Connett G; Dominguez-Munoz E; Levy P; Staab D; Williamson N; Lerch MM
    Patient; 2017 Oct; 10(5):615-628. PubMed ID: 28332032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.